MUMBAI: Shares in India's Ranbaxy Laboratories Ltd dropped more than 30 percent on Monday, after the U.S. Food and Drug Administration issued an import alert against company's Mohali plant.
The FDA issued the alert on Friday, as per FDA's website. A spokesman for Ranbaxy did not have immediate comment on the FDA action.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!